67 Maruyama, W. *et al.* (2002) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. *J. Neural Transm.* 109, 467–481

68 Du, Y. *et al.* (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. *Proc. Natl. Acad. Sci. U. S. A.* 98, 14669–14674

69 Le, W. *et al.* (2001) Microglial activation and dopaminergic cell injury: an *in vitro* model relevant to Parkinson's disease. *J. Neurosci.* 21, 8447–8455

70 Youdim, M.B. *et al.* (2001) Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. *Adv. Neurol.* 86, 115–124

71 Mouradian, M.M. (2002) Recent advances in the genetics and pathogenesis of Parkinson's disease. *Neurology* 58, 179–185

72 Junn, E. and Mouradian, M.M. (2002) Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. *Neurosci. Lett.* 320, 146–150

73 Kruger, R. *et al.* (2002) Parkinson's disease: one biochemical pathway to fit all genes? *Trends Mol. Med.* 8, 236–240

74 Chung, K.K. *et al.* (2001) The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. *Trends Neurosci.* 24 (Suppl.), S7–S14

75 Grunblatt, E. *et al.* (2001) Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. *J. Neurochem.* 78, 1–12

76 Rosen, D.R. *et al.* (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* 362, 59–62

77 Gurney, M.E. *et al.* (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. *Science* 264, 1772–1775

78 Wong, P.C. *et al.* (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. *Neuron* 14, 1105–1116

79 Cluskey, S. and Ramsden, D.B. (2001) Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. *J. Clin. Pathol.* 54, 386–392

80 Shaw, C.E. *et al.* (2001) Progress in the pathogenesis of amyotrophic lateral sclerosis. *Curr. Neurol. Neurosci. Rep.* 1, 69–77

81 Rothstein, J.D. *et al.* (1990) Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. *Ann. Neurol.* 28, 18–25

82 Bensimon, G. *et al.* (2002) A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. *J. Neurol.* 249, 609–615

83 Jackson, M. *et al.* (1999) Polymorphisms in the glutamate transporter gene EAAT2 in European ALS patients. *J. Neurol.* 246, 1140–1144

84 Trotti, D. *et al.* (2001) Amyotrophic lateral sclerosis-linked glutatmate transporter mutant has impaired glutamate clearance capacity. *J. Biol. Chem.* 276, 576–582

85 Bristol, L.A. and Rothstein, J.D. (1996) Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. *Ann. Neurol.* 39, 676–679

86 Shaw, P.J. and Eggett, C.J. (2000) Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. *J. Neurol.* 247 (Suppl. 1), 17–27

87 Comi, G.P. *et al.* (1998) Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. *Ann. Neurol.* 43, 110–116

88 Borthwick, G.M. *et al.* (1999) Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. *Ann. Neurol.* 46, 787–790

89 Strong, M.J. (1999) Neurofilament metabolism in sporadic amyotrophic lateral sclerosis. *J. Neurol. Sci.* 169, 170–177

90 Beaulieu, J.M. *et al.* (1999) Late onset death of motor neurons in mice overexpressing wild-type peripherin. *J. Cell Biol.* 147, 531–544

91 Ikeda, K. *et al.* (1996) Coadministration of interleukin-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse neuron disease. *Brain Res.* 726, 91–97

92 Kurek, J.B. *et al.* (1998) LIF (AM424), a promising growth factor for the treatment of ALS. *J. Neurol. Sci.* 160 (Suppl. 1), 6–13

93 Askanas, V. (1995) Neurotrophic factors and amyotrophic lateral sclerosis. *Adv. Neurol.* 68, 241–244

94 Apfel, S.C. (2001) Neurotrophic factor therapy – prospects and problems. *Clin. Chem. Lab. Med.* 39, 351–355

95 Alvarez, A. *et al.* (1999) Inhibition of tau phosphorylating protein kinase cdk5 prevents β-amyloid-induced neuronal death. *FEBS Lett.* 459, 421–426

96 Nguyen, M.D. *et al.* (2001) Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. *Neuron* 30, 135–147

Erratum

Please note a correction to the article *Structural pharmacogenomics, drug resistance and the design of anti-infective super-drugs* by Edward T. Maggio, Mark Shenderovich, Ron Kagan, Dean Goddette and Kal Ramnarayan in the print version of *Drug Discovery Today*, 15th December 2002, Volume 7, No. 24, 1214–1220.

Figure 7 on p. 1217 should have been as below:



Fig. 7. The number of amino acid classes allowed at each residue position for HIV-1 reverse transcriptase. 38 positions (flagged below the X-axis) frequently exhibit mutation to an amino acid class different from the original class.

We would like to apologize for this inaccuracy and for any confusion that this might have caused.

PII: S1359-6446(02)02577-1